Angiotensin-receptor blockade, cancer, and concerns.

摘要

As leaders of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, we feel obligated to point out a shortcoming in like Sipahi and colleagues' meta-analysis of cancer rates in patients treated with angiotensin-receptor blockers (ARBs) published recently in this journal.